The shift toward GLP-1 RAs and SGLT-2 inhibitors—combined with expanding cardiovascular-, renal- and obesity-related indications—creates upward expenditure pressure that may require future adjustments in pricing negotiations, reimbursement criteria or therapeutic guidelines. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.